Gland Pharma Limited Total Assets
Gland Pharma Limited total assets. Based on the latest financial reports, Gland Pharma Limited (GLAND) holds total assets worth Rs125.11 Billion INR (≈ $1.35 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GLAND company net worth for the company's overall valuation and market capitalisation.
Total Assets of Gland Pharma Limited (2017–2026)
Total assets of Gland Pharma Limited from 2017 to 2026. This chart illustrates how Gland Pharma Limited's total assets have evolved over time, based on quarterly financial data. See current stock price of Gland Pharma Limited for real-time trading data and today's change.
Gland Pharma Limited - Asset Composition Analysis
Gland Pharma Limited Total Assets Breakdown (March 2026)
Gland Pharma Limited total assets breakdown as of March 2026. Gland Pharma Limited's total assets of Rs125.11 Billion consist of 60.2% current assets and 39.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 26.9% |
| Accounts Receivable | Rs18.91 Billion | 15.1% |
| Inventory | Rs17.44 Billion | 13.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs1.09 Billion | 0.9% |
| Goodwill | Rs2.94 Billion | 2.4% |
Asset Composition Trend (2017–2026)
This chart illustrates how Gland Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Gland Pharma Limited (GLAND) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gland Pharma Limited's current assets represent 60.2% of total assets in 2026, an increase from 56.9% in 2017.
- Cash Position: Cash and equivalents constituted 26.9% of total assets in 2026, up from 21.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 15.1% of total assets.
Gland Pharma Limited Competitors by Total Assets
Key competitors of Gland Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Gland Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.68 | 4.33 | 10.00 |
| Quick Ratio | 3.60 | 3.26 | 7.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs59.18 Billion | Rs52.18 Billion | Rs46.11 Billion |
Gland Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Gland Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.64 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 11.5% |
| Total Assets | Rs125.11 Billion |
| Market Capitalization | $5.64 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Gland Pharma Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gland Pharma Limited's assets grew by 11.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gland Pharma Limited (2017–2026)
The table below shows the annual total assets of Gland Pharma Limited from 2017 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs125.11 Billion ≈ $1.35 Billion |
+11.46% |
| 2025-03-31 | Rs112.25 Billion ≈ $1.21 Billion |
+5.29% |
| 2024-03-31 | Rs106.61 Billion ≈ $1.15 Billion |
+21.46% |
| 2023-03-31 | Rs87.78 Billion ≈ $949.26 Million |
+12.05% |
| 2022-03-31 | Rs78.34 Billion ≈ $847.18 Million |
+20.59% |
| 2021-03-31 | Rs64.96 Billion ≈ $702.53 Million |
+58.98% |
| 2020-03-31 | Rs40.86 Billion ≈ $441.89 Million |
+15.96% |
| 2019-03-31 | Rs35.24 Billion ≈ $381.06 Million |
+20.28% |
| 2018-03-31 | Rs29.29 Billion ≈ $316.81 Million |
+18.42% |
| 2017-03-31 | Rs24.74 Billion ≈ $267.53 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The … Read more